Related Experiment Video

Updated: May 26, 2026

HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis
06:12

HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis

Published on: June 24, 2019

A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo

Yonghyo Kim1, Hye Jin Jung, Ho Jeong Kwon

  • 1Department of Biotechnology, Translational Research Center for Protein Function Control, College of Life Science & Biotechnology, Yonsei University, Seoul, Republic of Korea.

Biochemical and Biophysical Research Communications
|December 14, 2011
PubMed

Insights

Voacangine, a natural compound, effectively inhibits new blood vessel formation (angiogenesis) without toxicity. This discovery offers a promising new avenue for developing anti-cancer therapies targeting angiogenesis.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • Angiogenesis is crucial for tumor growth and metastasis.
  • Developing anti-angiogenic agents is a key cancer treatment strategy.
  • Voacanga africana is a plant source for potential therapeutic compounds.

Purpose of the Study:

  • To identify and characterize novel anti-angiogenic compounds.
  • To investigate the anti-angiogenic potential of voacangine, isolated from Voacanga africana.

Main Methods:

  • In vitro assays: HUVEC proliferation, VEGF-induced tube formation, chemoinvasion.
  • In vivo assays: Chorioallantoic membrane angiogenesis assay.
  • Molecular analysis: Hypoxia-inducible factor-1α (HIF-1α) and VEGF expression levels.

Main Results:

  • Voacangine inhibited HUVEC proliferation (IC50 = 18 μM) without cytotoxicity.
  • Suppressed in vitro angiogenesis (tube formation, chemoinvasion) and in vivo angiogenesis.
  • Dose-dependently reduced HIF-1α and VEGF expression.

Conclusions:

  • Voacangine is a novel, naturally occurring anti-angiogenic compound.
  • It demonstrates potential for cancer therapy by inhibiting key angiogenesis pathways.
  • Further research into voacangine as an anti-cancer agent is warranted.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Rat Mesentery Angiogenesis Assay18:30

Rat Mesentery Angiogenesis Assay

Published on: June 18, 2011

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Overview of Cell-Matrix Interactions01:24

Overview of Cell-Matrix Interactions

The extracellular matrix or ECM holds cells together to form a tissue and allows the cells within the tissue to communicate. ECM comprises proteins such as fibronectin, collagen, laminin, etc. The most abundant protein in this space is collagen. Collagen fibers are interwoven with carbohydrate-containing protein molecules called proteoglycans. ECM allows cell migration and provides a structural scaffold at cell adhesion that anchors the cell when the extracellular matrix proteins interact with...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...